GlassScriptPhysician profile
Gregory W Demeo
NPI 1497712657
$3,103.07
in general payments reported to CMS, 2019-2025
37 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $427 · 2021: $426 · 2022: $337 · 2023: $172 · 2024: $295 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.09 |
| Education | $151.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $700.00 | 2019 | |
| Amgen INC. | $551.36 | 2019-2025 | Evenity, Prolia |
| Millicent US INC | $210.14 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Pfizer INC. | $177.93 | 2020-2024 | |
| Astellas Pharma US INC | $124.75 | 2019-2023 | |
| Coopersurgical, INC. | $115.82 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Agile Therapeutics, INC. | $97.40 | 2021-2022 | |
| Renovia INC | $82.67 | 2020 | |
| Medtronic, INC. | $81.77 | 2021 | |
| Evofem Biosciences, INC. | $78.39 | 2021-2024 | |
| Therapeuticsmd, INC. | $76.58 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $76.47 | 2024-2025 | Myfembree |
| Abbvie INC. | $71.64 | 2019-2021 | |
| Daiichi Sankyo INC. | $61.56 | 2020-2022 | |
| Covidien LP | $58.51 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $58.17 | 2019-2022 | |
| Meditrina | $52.00 | 2023 | |
| Amag Pharmaceuticals, INC. | $49.27 | 2019-2020 | |
| Hologic Sales and Service, LLC | $43.20 | 2021 | |
| Sage Therapeutics, LLC | $40.16 | 2023-2025 | Zurzuvae |
| Myovant Sciences INC. | $37.54 | 2021-2022 | |
| Exeltis, USA INC. | $24.40 | 2019-2020 | |
| Aspira Women'S Health INC | $23.27 | 2020 | |
| Abbott Laboratories | $19.33 | 2022 | |
| Mayne Pharma Commercial LLC | $19.25 | 2021 | |
| Mylan Pharmaceuticals INC. | $18.70 | 2022 | |
| Avion Pharmaceuticals | $18.31 | 2022 | |
| Coloplast Corp | $18.04 | 2019 | |
| Lupin INC. | $16.75 | 2020 | |
| Roche Diagnostics Corporation | $15.89 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.40 | 2022 | |
| Duchesnay USA Incorporated | $15.26 | 2019 | |
| Exact Sciences Corporation | $14.25 | 2025 | The Cologuard Plus Collection Kit |
| Minerva Surgical, INC | $13.63 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $13.13 | 2021 | |
| Allergan, INC. | $12.13 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Demeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.